Kinderen et al. Side-effects of antiepileptic drugs: the economic burden. Seizure 23, 184–190 (2014).
Zullo, A., Large, M., Amoros, E. & Martin, J.-L. Estimated number of seriously injured road users admitted to hospital in France between 2010 and 2017, based on medico-administrative data. BMC Public Health 21, 469 (2021).
Sultana, J., Cutroneo, P. & Trifirò, G. Clinical and economic burden of adverse drug reactions. J. Pharmacol. Pharmacother. 4, S73–S77 (2013).
Elzagallaai, A., Greff, M. & Rieder, M. Adverse drug reactions in children: the double-edged sword of therapeutics. Clin. Pharmacol. Ther. 101, 725–735 (2017).
Larcher, V. in Handbook of the Philosophy of Medicine (eds Schramme, T. & Edwards, S.) 1–23 (Springer Netherlands, 2015). https://doi.org/10.1007/978-94-017-8706-2_16-1.
Giangreco, N. P., Elias, J. E. & Tatonetti, N. P. No population left behind: improving paediatric drug safety using informatics and systems biology. Br. J. Clin. Pharmacol. 88, 1464–1470 (2022).
Hines, R. N. Ontogeny of human hepatic cytochromes P450. J. Biochem. Mol. Toxicol. 21, 169–175 (2007).
van der Zanden, T. M. et al. Developing a paediatric drug formulary for the Netherlands. Arch. Dis. Child. 102, 357–361 (2017).
Smyth, R. M. D. et al. Adverse drug reactions in children—a systematic review. PLoS ONE 7, e24061 (2012).
Impicciatore, P. et al. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br. J. Clin. Pharmacol. 52, 77–83 (2001).
Tripathy, R., Das, S., Das, P., Mohakud, N. K. & Das, M. Adverse drug reactions in the pediatric population: findings from the adverse drug reaction monitoring center of a teaching hospital in odisha (2015-2020). Cureus 13, e19424 (2021).
Alghamdi, A. A. et al. Incidence and nature of adverse drug events in paediatric intensive care units: a prospective multicentre study. Br. J. Clin. Pharmacol. 88, 2213–2222 (2022).
Eulmesekian, P. G. et al. The occurrence of adverse events is associated with increased morbidity and mortality in children admitted to a single pediatric intensive care unit. Eur. J. Pediatr. 179, 473–482 (2020).
Jong, G. W. ‘t et al. Unapproved and off-label use of drugs in a children’s hospital. N. Engl. J. Med. 343, 1125 (2000).
Costa, H. T. M., de, Costa, L., Martins, T. X. & Oliveira, R. R. A. G. Use of off-label and unlicensed medicines in neonatal intensive care. PLoS ONE 13, e0204427 (2018).
Budetti, P. P. Ensuring safe and effective medications for children. JAMA 290, 950–951 (2003).
Shuib, W., Wu, X.-Y. & Xiao, F. Extent, reasons and consequences of off-labeled and unlicensed drug prescription in hospitalized children: a narrative review. World J. Pediatr. 17, 341–354 (2021). WJP.
Toma, M. et al. Paediatric medicines in Europe: the paediatric regulation-is it time for reform?. Front. Med. 8, 593281 (2021).
Ceci, A. et al. in Drug Discovery and Development—from Molecules to Medicine (IntechOpen, 2015). https://doi.org/10.5772/60611.
Hwang, T. J., Orenstein, L., Kesselheim, A. S. & Bourgeois, F. T. Completion rate and reporting of mandatory pediatric postmarketing studies under the US pediatric research equity act. JAMA Pediatr. 173, 68–74 (2019).
Wharton, G. T. et al. Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy. Pediatrics 134, e512–518 (2014).
Li, Y. et al. Opportunities and challenges of pharmacovigilance in special populations: a narrative review of the literature. Ther. Adv. Drug Saf. 14, 20420986231200746 (2023).
Giangreco, N. P. & Tatonetti, N. P. A database of pediatric drug effects to evaluate ontogenic mechanisms from child growth and development. Med 3, 579–595.e7 (2022).
Reinblatt, S. P., DosReis, S., Walkup, J. T. & Riddle, M. A. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents. J. Child Adolesc. Psychopharmacol. 19, 119–126 (2009).
Rasmussen, C. et al. Drug-induced IgA vasculitis in children and adults: revisiting drug causality using a dual pharmacovigilance-based approach. Autoimmun. Rev. 20, 102707 (2021).
Zhao, H., Zhong, J., Liang, X., Xie, C. & Wang, S. Application of machine learning in drug side effect prediction: databases, methods, and challenges. Front. Comput. Sci. 19, 195902 (2025).
Nguyen, D. A., Nguyen, C. H. & Mamitsuka, H. A survey on adverse drug reaction studies: data, tasks and machine learning methods. Briefings Bioinf. 22, 164–177 (2021).
Galeano, D., Li, S., Gerstein, M. & Paccanaro, A. Predicting the frequencies of drug side effects. Nat. Commun. 11, 4575 (2020).
Farnoush, A., Sedighi-Maman, Z., Rasoolian, B., Heath, J. J. & Fallah, B. Prediction of adverse drug reactions using demographic and non-clinical drug characteristics in FAERS data. Sci. Rep. 14, 23636 (2024).
Zhao, H. et al. Identifying the serious clinical outcomes of adverse reactions to drugs by a multi-task deep learning framework. Commun. Biol. 6, 1–14 (2023).
Gao, Y. et al. Precision adverse drug reactions prediction with heterogeneous graph neural network. Adv. Sci. 12 (2025).
Goldman, S. A. Limitations and strengths of spontaneous reports data. Clin. Ther. 20, C40–44 (1998).
Kuhn, M., Letunic, I., Jensen, L. J. & Bork, P. The SIDER database of drugs and side effects. Nucleic Acids Res. 44, D1075–D1079 (2016).
Stricker, B. H. & Tijssen, J. G. Serum sickness-like reactions to cefaclor. J. Clin. Epidemiol. 45, 1177–1184 (1992).
Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10, 483–486 (2001).
Szarfman, A., Machado, S. G. & O’Neill, R. T. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Saf 25, 381–392 (2002).
Bate, A. et al. A bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315–321 (1998).
Van Puijenbroek, E. P. et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidem. Dr. S. 11, 3–10 (2002).
Wilson, A. M., Thabane, L. & Holbrook, A. Application of data mining techniques in pharmacovigilance. Br. J. Clin. Pharmacol. 57, 127–134 (2004).
Bertoni, M. et al. Bioactivity descriptors for uncharacterized chemical compounds. Nat. Commun. 12, 3932 (2021).
Lundberg, S. & Lee, S.-I. A unified approach to interpreting model predictions. Preprint at https://doi.org/10.48550/arXiv.1705.07874 (2017).
Tátrai, P. & Krajcsi, P. Prediction of drug-induced hyperbilirubinemia by in vitro testing. Pharmaceutics 12, 755 (2020).
Wanat, K. Biological barriers, and the influence of protein binding on the passage of drugs across them. Mol. Biol. Rep. 47, 3221–3231 (2020).
Lim, S. Y. & Pettit, R. S. Pharmacokinetic considerations in pediatric pharmacotherapy. Am. J. Health-syst. Pharm. 76, 1472–1480 (2019).
Verstegen, R. H. J., Anderson, P. O. & Ito, S. Infant drug exposure via breast milk. Br. J. Clin. Pharmacol. 88, 4311–4327 (2022).
Sutherland, J. M. Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. A.M.A. J. Dis. Child. 97, 761–767 (1959).
Frey, B., Braegger, C. P. & Ghelfi, D. Neonatal cholestatic hepatitis from carbamazepine exposure during pregnancy and breast feeding. Ann. Pharmacother. 36, 644–647 (2002).
Rodríguez-Vázquez, M., Carrascosa-Romero, M. C., Pardal-Fernández, J. M. & Iniesta, I. Congenital gingival hyperplasia in a neonate with foetal valproate syndrome. Neuropediatrics 38, 251–252 (2008).
Mkhitaryan, M., Avetisyan, T., Mkhoyan, A., Avetisyan, L. & Yenkoyan, K. A case–control study on pre-, peri-, and neonatal risk factors associated with autism spectrum disorder among Armenian children. Sci. Rep. 14, 12308 (2024).
Singh, G. K. et al. Opioid epidemic in the United States: empirical trends, and a literature review of social determinants and epidemiological, pain management, and treatment patterns. Int. J. MCH AIDS 8, 89–100 (2019).
Velez, M. L., Jordan, C. J. & Jansson, L. M. Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach. Neurotoxicol. Teratol. 88, 107020 (2021).
Baldo, B. A. Current research in pathophysiology of opioid-induced respiratory depression, neonatal opioid withdrawal syndrome, and neonatal antidepressant exposure syndrome. Curr. Res. Toxicol. 3, 100078 (2022).
Creeley, C. E. & Denton, L. K. Use of prescribed psychotropics during pregnancy: a systematic review of pregnancy, neonatal, and childhood outcomes. Brain Sci. 9, 235 (2019).
Shiff, I., Bucsea, O. & Pillai Riddell, R. Psychosocial and neurobiological vulnerabilities of the hospitalized preterm infant and relevant non-pharmacological pain mitigation strategies. Front. Pediatr. 9, 568755 (2021).
Bettina, B., Hans, H. & Matthias, L. Severe methemoglobinemia caused by continuous lidocaine infusion in a term neonate. Eur. J. Paediatr. Neurol. 21, 576–579 (2017).
Kozma, C. Neonatal toxicity and transient neurodevelopmental deficits following prenatal exposure to lithium: another clinical report and a review of the literature. Am. J. Med. Genet. A 132A, 441–444 (2005).
Salim, H., Musmar, B., A Sarhan, F. M., Giacaman, N. & Abu Omar, S. The first-reported case of drug-induced hemolytic anemia by piperacillin-tazobactam in a premature neonate: a case report and literature review. Cureus https://doi.org/10.7759/cureus.35915 (2023).
Neonatal abstinence syndrome: MedlinePlus medical encyclopedia. https://medlineplus.gov/ency/article/007313.htm.
Kearns, G. L. et al. Developmental pharmacology−drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157–1167 (2003).
Stenius-Aarniala, B., Riikonen, S. & Teramo, K. Slow-release theophylline in pregnant asthmatics. Chest 107, 642–647 (1995).
Noetzel, M. J. Theophylline neurotoxicity resulting in significant unilateral brain-damage. Dev. Med. Child Neurol. 27, 242–245 (1985).
Nord, C. L. et al. Neural effects of antidepressant medication and psychological treatments: a quantitative synthesis across three meta-analyses. Br. J. Psychiatry: J. Ment. Sci. 219, 546–550 (2021).
Spirko, B. A. Serotonin syndrome: a new pediatric intoxication. Pediatr. Emerg. Care 15, 440 (1999).
Al-Dhaher, Z. et al. Activating and tranquilizing effects of first-time treatment with aripiprazole, olanzapine, quetiapine, and risperidone in youth. J. Child Adolesc. Psychopharmacol. 26, 458–470 (2016).
Seifert, Schwartz, S. A., Michael, D. & & Thomas, J. D. Aripiprazole (abilifyTM) overdose in a child. Clin. Toxicol. 43, 193–195 (2005).
Saikia, D. & Mahanta, B. Cardiovascular and respiratory physiology in children. Indian J. Anaesth. 63, 690–697 (2019).
Običan, S. G. & Yankowitz, J. in Critical Care Obstetrics 151–174 (John Wiley & Sons, Ltd, 2018). https://doi.org/10.1002/9781119129400.ch9.
Kusters, D. M. et al. Dilemmas in treatment of women with familial hypercholesterolaemia during pregnancy. Neth. J. Med. 68, 299–303 (2010).
Rieder, M. Adverse drug reactions in children: pediatric pharmacy and drug safety. J. Pediatr. Pharmacol. Ther. 24, 4–9 (2019).
Blake, K. V. et al. Comparison between paediatric and adult suspected adverse drug reactions reported to the european medicines agency: implications for pharmacovigilance. Paediatr. Drugs 16, 309–319 (2014).
Star, K., Norén, G. N., Nordin, K. and Edwards, I. R. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase. Drug Saf. 34 (2011).
Star, K. Detecting unexpected adverse drug reactions in children. Paediatr. Drugs 13, 71–73 (2011).
Iheonu, F. O., Fajolu, I. B., Ezeaka, C. V. & Oyibo, W. A. Transfusional malaria in the neonatal period in lagos, south-west Nigeria. PLoS ONE 13, e0195319 (2018).
Hochberg, Z. Uncoupling of the infancy life history stage. Horm. Res. Paediatr. 94, 161–167 (2021).
Perszyk, D. R. & Waxman, S. R. Linking language and cognition in infancy. Annu. Rev. Psychol. 69, 231–250 (2018).
Bánfai-Csonka, H. et al. Health literacy in early childhood: a systematic review of empirical studies. Children 9, 1131 (2022).
Brown, E. G., Wood, L. & Wood, S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 20, 109–117 (1999).
Knox, C. et al. DrugBank 6.0: the DrugBank Knowledgebase for 2024. Nucleic Acids Res. gkad976 https://doi.org/10.1093/nar/gkad976 (2023).
Buckley, N. A. & Rossi, S. Bringing greater transparency to ‘black box’ warnings. Clin. Toxicol. (Phila.) 49, 448–451 (2011).
Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10, 796–803 (2013).
Yongyang, X., Yanming, X. & Danhui, Y. Pharmacovigilance of major parmaceutical innovation. Zhongguo Zhongyao Zazhi 36, 2831–2835 (2011).
DuMouchel, W. & Pregibon, D. Empirical bayes screening for multi-item associations. In Proc. 7th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining 67–76 (ACM, 2001). https://doi.org/10.1145/502512.502526.
Tan, J. et al. Data mining and analysis for iodinated contrast media adverse event signals based on the food and drug administration adverse event reporting system database. Clin. Ther. 47, 82–90 (2025).
Mendez, D. et al. ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res. 47, D930–D940 (2019).
Hollmann, N. et al. Accurate predictions on small data with a tabular foundation model. Nature 637, 319–326 (2025).
Jilani, S. M. et al. Standardizing the clinical definition of opioid withdrawal in the neonate. J. Pediatr. 243, 33–39.e1 (2022).
Gershanik, J., Boecler, B., Ensley, H., McCloskey, S. & George, W. The gasping syndrome and benzyl alcohol poisoning. N. Engl. J. Med. 307, 1384–1388 (1982).
Barry, J. M., Birnbaum, A. K., Jasin, L. R. & Sherwin, C. M. Maternal exposure and neonatal effects of drugs of abuse. J. Clin. Pharmacol. 61, S142–S155 (2021).
Belik, J. Fetal and neonatal effects of maternal drug treatment for depression. Semin. Perinatol. 32, 350–354 (2008).
Lakshminrusimha, S. The pulmonary circulation in neonatal respiratory failure. Clin. Perinatol. 39, 655–683 (2012).
van der Lugt, N. M. et al. Fetal, neonatal and developmental outcomes of lithium-exposed pregnancies. Early Hum. Dev. 88, 375–378 (2012).
Gunes, A., Balik, H., Yel, S., Kocamaz, H. & Bosnak, M. Respiratuvar depression after accidental nasal ingestion of brimonidine eye drops in infant. Turk. J. Emerg. Med. 16, 169–170 (2016).
Refetoff, S., Ochi, Y., Selenkow, H. A. & Rosenfield, R. L. Neonatal hypothyroidism and goiter in one infant of each of two sets of twins due to maternal therapy with antithyroid drugs. J. Pediatr. 85, 240–244 (1974).
Girardi, A. et al. Drug-induced renal damage in preterm neonates: state of the art and methods for early detection. Drug Saf. 38, 535–551 (2015).
Boubred, F. et al. Effects of maternally administered drugs on the fetal and neonatal kidney. Drug Saf. 29, 397–419 (2006).
Rigg, K. K. & Rigg, M. S. Opioid-induced hearing loss and neonatal abstinence syndrome: clinical considerations for audiologists and recommendations for future research. Am. J. Audiol. 29, 701–709 (2020).
McWilliam, S. J., Antoine, D. J., Smyth, R. L. & Pirmohamed, M. Aminoglycoside-induced nephrotoxicity in children. Pediatr. Nephrol. 32, 2015–2025 (2017).
Puertas Sanjuan, A., Parramón-Teixidó, C. J., Hernandez-Perez, S., Frick, M. A. & Cabañas Poy, M. J. Persistent dyselectrolytemia in a neonate induced by liposomal amphotericin B. A case report. Front. Pediatr. 10 (2023).
Wackernagel, D., Obaya, S. & Nydert, P. Dalteparin-sodium induced drug fever in a neonate. Case Rep. 2016, bcr2016217621 (2016).
